Calfactant is a lung surfactant for the prophylaxis of respiratory distress syndrome in high-risk infants. Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation.
- Mechanism
- Curator reviewed
Pulmonary surfactant is an endogenous substance produced in the lungs that functions to decrease surface tension at the air:fluid interface on the alveolar surface. In premature infants with pulmonary surfactant deficiency, surface tension can increase to the point where sections of lung collapse and respiratory distress syndrome (RDS) develops. Calfactant adsorbs rapidly to the surface of the alveolar air:fluid interface and modifies surface tension to a minimum of less than 3 mN/m. It acts in a manner similar to natural lung surfactant, thus preventing or treating respiratory distress syndrome.
- Primary indication
- Calfactant is indicated for prophylaxis therapy to prevent respiratory distress syndrome (RDS) in premature infants <29 weeks of gestational age with low lung surfactant and at high risk for RDS.Curator reviewed · 2 structured indications
- First approval
- Canada, 2002 · United States, 1999
- Also known as
- AeroFact · Alveofact · Bovactant · SF-RI 1
- Brand names
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with Calfactant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account